Sirtinol Treatment Reduces Inflammation in Human Dermal Microvascular Endothelial Cells
Author Information
Author(s): Orecchia Angela, Scarponi Claudia, Di Felice Francesca, Cesarini Elisa, Avitabile Simona, Mai Antonello, Mauro Maria Luisa, Sirri Valentina, Zambruno Giovanna, Albanesi Cristina, Camilloni Giorgio, Failla Cristina M.
Primary Institution: Molecular and Cell Biology Laboratory, IDI-IRCCS, Rome, Italy
Hypothesis
Can sirtinol, a specific sirtuin inhibitor, reduce inflammatory responses in human dermal microvascular endothelial cells (HDMEC)?
Conclusion
Sirtinol treatment significantly reduces inflammatory responses in HDMEC, suggesting sirtuins as potential therapeutic targets for inflammatory skin diseases.
Supporting Evidence
- Sirtinol treatment alone affected only long-term cell proliferation.
- Sirtinol significantly reduced membrane expression of adhesion molecules in TNFα- or IL-1β-stimulated cells.
- Sirtinol drastically decreased monocyte adhesion on activated HDMEC.
- Sirt1 inhibition was shown to be involved in the modulation of adhesion molecule expression.
Takeaway
This study shows that a drug called sirtinol can help calm down inflammation in skin cells, which might be useful for treating skin diseases.
Methodology
The study involved treating human dermal microvascular endothelial cells with sirtinol and analyzing their response to inflammatory cytokines using flow cytometry and ELISA.
Limitations
The study primarily focuses on in vitro results, which may not fully represent in vivo conditions.
Participant Demographics
HDMEC were isolated from foreskin of 4 different donors.
Statistical Information
P-Value
p≤0.005
Statistical Significance
p≤0.005
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website